FDA Approves Expanded Indication for KEYTRUDA® (pembrol

Approval is based on results from the Phase 3 KEYNOTE-A39 trial, which demonstrated a superior overall survival benefit with KEYTRUDA plus Padcev versus platinum-based chemotherapy (gemcitabine plus cisplatin or carboplatin) in these patientsApproval expands the use of KEYTRUDA plus Padcev for locally advanced or me...

Related Keywords

Canada , United States , Damini Chokshi , Chrissy Trank , Julie Cunningham , Peter Dannenbaum , Pfizer , European Society For Medical Oncology Congress , Drug Administration , European Society , Medical Oncology Congress , Presidential Symposium , Time Oncology Review , Bacillus Calmette Guerin , Selected Important Safety , Important Safety Information , Fatal Immune Mediated Adverse , Which Can Present With Diabetic ,